Introduction
New onset refractory status epilepticus (NORSE) in adults can be difficult to treat especially in cases where the etiology remains unknown, despite extensive evaluation including autoimmune, infectious and metabolic studies. 1 These patients present a therapeutic challenge because outcome is often poor due to prolonged hospitalization. Etiology is often presumed to be viral encephalitis based on MR imaging abnormalities or mild CSF pleocytosis, however, some of these changes may be due to the seizure activity itself. 2, 3 We report our experience with 3 patients with NORSE who responded to plasma exchange therapy after multiple anticonvulsants and general anesthetics failed. While much is still unknown about this disease entity, our experience suggests that immune therapies should be considered early on in the hospital course to prevent high morbidity and mortality.
Case reports

Patient 1
A 43-year-old African-American woman with no prior history of seizures and no risk factors for epilepsy presented with her first generalized tonic-clonic seizure and a preceding flu-like illness. Initial EEG showed background slowing and a brain MRI was normal. She was discharged home with phenytoin, but developed progressive confusion over the next 3 days and was readmitted. A stat EEG showed bitemporal independent focal seizures. She was initiated on fosphenytoin and levetiracetam intravenously. Her CSF analysis, MRI brain and laboratory data are shown in Table 1 and Fig. 1B . The MRI showed bilateral hippocampal hyperintensities, suspicious for limbic encephalitis. Her continuous EEG (cEEG) monitoring showed approximately 2 seizures/h originating from bilateral temporal lobes lasting 30-90 s (Fig. 1A) . Given no improvement in seizures on EEG, she was treated with phenobarbital, then propofol infusion and was finally placed in a pentobarbital coma to achieve burst suppression of EEG activity for 48 h. Seizures returned promptly when pentobarbital was lightened and so the barbiturate coma was repeated again for 96 h. A trial of methylprednisolone 1 g daily for 3 days was given simultaneously with no improvement and seizures resumed as pentobarbital was withdrawn. On day 18 of hospitalization, plasma exchange (PE) therapy was instituted for 5 days, as she remained on a midazolam infusion. On the fourth day of treatment, her EEG began to improve with resolution of seizures and the Objective: New onset refractory status epilepticus (NORSE) is a recently described entity and has been difficult to treat because the etiology is often cryptogenic. Our aim in each case was to stop status epilepticus while simultaneously searching for the etiology. Methods: We describe three patients who presented with NORSE, who were refractory to multiple anticonvulsants and general anesthetics for at least 5 days. All patients had an extensive evaluation including MRI brain, CSF studies, radiologic scans for malignancy and serological autoimmune and infectious investigations. Results: Each patient responded dramatically to the use of plasma exchange therapy with cessation of status epilepticus by the fourth day of treatment. Although an etiology was sought after, no appropriate cause for NORSE could be found.
Conclusion:
We propose early use of plasma exchange therapy (Class IV evidence) in hopes to prevent the complications of status epilepticus and prolonged hospitalization. 
Patient 2
A 51-year-old Hispanic male initially presented with a febrile illness and a suspected complex partial seizure. However, he had normal CSF findings and routine EEG. He was started on carbamazepine, but stopped the medication 2 weeks later on his own. Four months later, he returned with a 5-day history of confusion and lethargy. His CSF, MRI and laboratory evaluation are shown in Table 1 and Fig. 1C . An initial EEG showed intermittent focal seizures emanating from the right temporal region lasting from 20 to 120 s interspersed by a background of mild diffuse slowing. Initial MRI of the brain showed hyperintensities in bilateral hippocampi with subtle enhancement noted on the right. He was placed on cEEG monitoring and treated with fosphenytoin followed by levetiracetam and lacosamide, however, there was no improvement in mental status. On day 5 of hospitalization, plasma exchange was instituted for 5 days as he was maintained on the above anticonvulsants. After completing plasma exchange, antiepileptic medication was gradually weaned and seizures did not recur. Eventually, he was discharged on 2 anticonvulsants, phenytoin and lacosamide. At 6-month follow-up, he has recovered well, though he reports short-term memory loss and inability to return to work.
Patient 3
A 39-year-old previously healthy Caucasian/African-American woman presented with a flu-like illness 5 days prior to her first generalized tonic-clonic seizure. She was lethargic and confused at presentation. An initial EEG showed multiple bilateral independent seizures clinically characterized by eye blinking. She was initially treated with lorazepam followed by fosphenytoin and levetiracetam. A cEEG showed non-convulsive status epilepticus with bilateral periodic discharges at 2-3 Hz interspersed by brief electrographic seizures lasting 60-120 s. A propofol infusion initially suppressed seizures, but they returned promptly during weaning. Valproic acid and lacosamide were added, but did not improve SE. She was then placed in a pentobarbital coma on day 10. CSF, serological studies and brain MRI data are shown in Table 1 and Fig. 1D . She had serial brain MRIs which showed increasingly hyperintense hippocampal changes. Each time the pentobarbital infusion was decreased, bilateral independent periodic discharges along with intermittent independent bilateral focal seizures returned. During the second week, a 5-day course of intravenous immunoglobulin therapy followed by 5 days of high dose methylprednisolone did not improve her status. She developed an acute abdomen and at emergent laparotomy, was found to have severe bowel infarction. This was presumably due to prolonged use of vasopressors and nearly 90% of her bowels were resected. After surgery, given no improvement on EEG, other anesthetics including ketamine, midazolam and lorazepam infusions were attempted, but she continued to have seizures while on maximal doses of each of these agents. On day 29 of hospitalization, PE was instituted for 5 days. With simultaneous weaning of anesthetic infusions, she began opening her eyes spontaneously to voice and follow some commands. Her EEG showed diffuse slowing with frequent epileptiform discharges during sleep, but no further seizures. She was weaned off of all anesthetic agents and her seizures were controlled with oral lorazepam, phenobarbital, levetiracetam and lacosamide. However, her bowel condition deteriorated and she was eventually sent to hospice where she died quickly from respiratory failure. At autopsy, she was found to have necrotic bowel proximal to her ostomy site along with nonspecific inflammation of bilateral hippocampi. VDRL, bacterial and fungal cultures in CSF and serum. c A repeat test 13 days later showed titers were negative for IgM and positive for IgG, however, Mycoplasma was never detected in the CSF by PCR or in respiratory cultures, cold agglutinins and chest radiograph were also negative. 
Discussion
Our case series suggest that PE may be a beneficial in cases of NORSE even when etiology is unclear and typical paraneoplastic or anti-neuronal antibodies are not detected. There have been isolated case reports showing successful use of immune-modulating therapy in such cases. 4, 5 While the etiology was cryptogenic in each of our patients, it is certainly possible there are other antineuronal antibodies that have not yet been discovered and further testing of these patients' serum and CSF against animal models would be revealing. 6 We also could not test for the full range of known antibodies for proprietary reasons. Plasma exchange is also not selective, but removes other soluble factors including cryoglobulins, plasma proteins, immune complexes that may have contributed to SE. Of importance, each patient presented primarily with seizures and not psychiatric symptoms, but we can surmise that likely a portion of NORSE patients have some form of limbic encephalitis. However, diagnosis confirmation should not delay treatment. Also, the duration of SE should not deter aggressive treatment as it has not been shown to be a predictor of prognosis beyond the first few hours. 7 The average time for our patients to receive plasma exchange was 17 days from the time of initial hospitalization.
The use of multiple anti-epileptic agents and general anesthetics in these cases can cause severe cardiac, respiratory, and hemodynamic compromise 8 and unfortunately, our third patient suffered irreversible abdominal ischemic injury prior to cessation of her SE. One large series reported poor outcomes in about half of patients with RSE, with death (35%), severe neurological deficit (13%), mild neurological deficit (13%), and a minority had recovery to baseline (35%). 9 We suspect neurologists are more apt to use multiple anti-epileptic agents and general anesthetics in NORSE patients because these are generally previously healthy, young individuals. However, based upon our experience PE may be a potential beneficial therapy in cases of NORSE. A recent guideline for refractory status epilepticus also suggested using nonpharmacologic options as a part of their treatment algorithm. 10 Unfortunately, the nature of the NORSE makes it difficult to perform randomized controlled studies. But until then, we propose that plasma exchange should be considered in the treatment repertoire in cryptogenic NORSE cases, earlier rather than later to prevent associated morbidity and mortality.
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